Connect Biopharma Holdings (CNTB) FCF Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted FCF Margin of 9469.23% for Q1 2026, up 91.31% sequentially from 109000.0% in Q3 2025.

Connect Biopharma Holdings (CNTB) FCF Margin (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported FCF Margin for 3 years, with the latest figure at 9469.23% in Q1 2026.

Quarterly FCF Margin changed N/A year-over-year to 9469.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24795.71% (changed N/A YoY) and the FY2025 annual result came in at 80954.69%, down 8086111.0% from the prior year.
FCF Margin climbed to 9469.23% in Q1 2026 per CNTB's latest filing, from 109000.0% in the prior quarter.
Over five years, FCF Margin peaked at 377.08% in Q4 2024 and troughed at 109000.0% in Q3 2025.
A 3-year average of 29357.58% and a median of 9469.23% in 2026 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 10792092 bps in 2025, down 10792092 bps in 2025.
Over 3 years, FCF Margin stood at 377.08% in 2024, then sank by 28807 bps to 109000.0% in 2025, then surged by 91 bps to 9469.23% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 9469.23%, 109000.0%, and 26862.5% for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	-575.18%

Download Data